Abstract
Pharmacogenomics is the application of genomics technology to the discovery and development of drugs. A greater understanding of the way in which individuals with a particular genotype respond to a drug allows manufacturers to identify population subgroups that will benefit most from a particular drug. The increasing emphasis on pharmacogenomics is likely to raise ethical and legal questions regarding, among other things, the design of research studies, the construction of clinical trials and the pricing of drugs.
This is a preview of subscription content, log in via an institution to check access.
References
Lazarou, J., Pomeranz, B. H. & Corey, P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279, 1200–1205 (1998).
Flanagan, A. Screening technologies evolve: innovations spurred by race to profit from genetic data. Genet. Eng. News 20, 1, 19–20, 71 ( September 1, 2000).
Barrett, A. The pharma frenzy: in the race for gene-based therapies, big drugmakers join forces with upstarts. Business Week 160– 161 (June 2000).
Roses, A. D. Pharmacogenetics and the practice of medicine. Nature 405, 857–865 (2000).
Noah, B. A. Adverse drug reactions: harnessing experiential data to promote patient welfare . Catholic U. Law Rev. 49, 449– 504 (2000).
Roses, A. D. Pharmacogenetics and future drug development and delivery. Lancet 355, 1358–1361 ( 2000).
Richmond, M. H. et al. Human Genomics: Prospects for Health Care and Public Policy (Pharmaceutical Partners for Better Healthcare, England, 1999).
Wood, A. J. J. & Woosley, R. Making medicines safer—the need for an independent drug safety board. N. Engl. J. Med. 339, 1851–1853 (1998).
Rothstein, M. A. Genetic privacy and confidentiality: why they are so hard to protect. J. Law Med. Ethics 26, 198–204 (1998).
Meyer, U. A. Pharmacogenetics and adverse drug reactions. Lancet 356, 1667–1671 (2000).
Evans, W. E. & Relling, M. V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487–491 (1999).
Beutler, E. G6PD: population genetics and clinical manifestations. Blood Rev. 10, 45–52 ( 1996).
Weber, W. W. Pharmacogenetics Vol. 15 (Oxford Univ. Press, New York, 1997).
Grant, D. M. et al. Human acetyltransferase polymorphisms. Mutat Res. 376, 61–70 ( 1997).
Sharp, R. S. & Foster, M. W. Involving study populations in the review of genetic research. J. Law Med. Ethics 28, 41–50 (2000).
Juengst, E. T. Commentary: what 'community review' can and cannot do. J. Law Med. Ethics 28, 52–54 ( 2000).
Holmer, A. F. Correspondence: the pharmaceutical industry—to whom is it accountable? N. Engl. J. Med. 343, 1415 ( 2000).
Mrazek, M. F. & Mossialos, E. Increasing demand while decreasing costs of generic medicines. Lancet 356, 1784–1785 (2000).
Angell, M. The pharmaceutical industry—to whom is it accountable? N. Engl. J. Med. 342, 1902–1904 (2000).
Thamer, M. et al. A cross-national comparison of orphan drug policies: implications for the U. S. Orphan Drug Act. J. Hlth Politics Policy Law 23, 265–290 (1998).
Pulsinelli, G. A. The orphan drug act: what's right with it. Santa Clara Computer & High Technology Law J. 15, 299– 345 (1999).
Kuszler, P. C. Financing clinical research and experimental therapies: payment due, but from whom? DePaul J. Hlth Care Law 3, 441– 494 (2000).
Schoonmaker, M. M. et al. Factors influencing health insurers' decisions to cover new genetic technologies. Intl J. Technol. Assess. Hlth Care 16, 178–189 (2000).
Horner v. Spalitto, 1 S. W. 3d 519 (Mo. Ct. App. 1999) (reversing grant of summary judgement in favor of customer who died from overdose following accurate filling of incorrectly prescribed drug by pharmacist). Opinion
Cassidy v. Smithkline Beecham, No. 99-10423 (Pa. Chester County Dec. 14, 1999).
National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, The Belmont Report (April 18, 1979).
Emanuel, E. J., Wendler, D. & Grady, C. What makes clinical research ethical? JAMA 283, 2701–2711 ( 2000).
Acknowledgements
This work was supported by the National Institutes of Health. The authors are grateful to Joseph Wang for his research assistance.
Author information
Authors and Affiliations
Related links
Related links
DATABASE LINKS
FURTHER INFORMATION
European Agency for the Evaluation of Medicinal Products
The European Commission's report on orphan medicinal products
European Agency for the Evaluation of Medicinal Products
Pharmaceuticals Affairs Bureau
Journal of Health Politics, Policy and Law
Journal of International Law and Practice
Rights and permissions
About this article
Cite this article
Rothstein, M., Epps, P. Ethical and legal implications of pharmacogenomics . Nat Rev Genet 2, 228–231 (2001). https://doi.org/10.1038/35056075
Issue Date:
DOI: https://doi.org/10.1038/35056075
- Springer Nature Limited
This article is cited by
-
Data privacy protection in scientific publications: process implementation at a pharmaceutical company
BMC Medical Ethics (2022)
-
Perceptions of students in health and molecular life sciences regarding pharmacogenomics and personalized medicine
Human Genomics (2018)
-
Are patients willing to incur out-of-pocket costs for pharmacogenomic testing?
The Pharmacogenomics Journal (2017)